Uterine Fibroid Treatment Device Market Size was valued at USD 5.2 Billion in 2022. The Uterine Fibroid Treatment Device market industry is projected to grow from USD 5.73 Billion in 2023 to USD 12.46 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 10.20% during the forecast period (2023 - 2032).The main market driver fueling market expansion is the high frequency of uterine fibroids among women. 
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
Rising incidence of uterine fibroids is driving the market growth
One of the main factors boosting the market revenue growth is the increasing prevalence of uterine fibroids. According to the National Institutes of Health (NIH), 70% of white women and 80% of African American women in the United States, respectively, will have uterine fibroids by the time they are 50. The high prevalence of the condition is driving the demand for state-of-the-art uterine fibroids therapy equipment, such as Magnetic Resonance Imaging (MRI)-guided Focused Ultrasound (MRgFUS) and Radiofrequency Ablation (RFA) devices. These devices offer a non-invasive or slightly invasive substitute for popular surgical treatments including hysterectomy and myomectomy.
Additionally, an increase in patients' preferences for minimally invasive and non-invasive fibroids operations is anticipated to boost market expansion. Smaller incisions reduce post-operative pain and speed up recovery, which encourages widespread use of these procedures. A number of significant firms are investing in R&D to bring cutting-edge minimally invasive surgical devices to market. One of the incisionless techniques that is highly suggested by doctors is the MR-guided Focused Ultrasound (MRgFUS) used to treat uterine fibroids.
Targeted tissue from the uterine cavity is heated and removed during this treatment by the device's ultrasonic beams. Since this is a non-invasive procedure, there are little to no side effects, and patients can resume their regular activities in a few days. Thus, it is projected that the market for uterine fibroids treatment devices would increase due to the increased demand for such operations due to their minimum pain, effectiveness, reduced risk of infection, and quick recovery as compared to open surgeries.
Various governments and commercial groups are launching a number of campaigns to raise awareness about early fibroids detection and treatment. For instance, July is "Fibroids Awareness Month" in the United States. Uterine fibroids have been the subject of expanded awareness campaigns in recent years. The White Dress Project, HealthyWomen.org, Fibroids Project, and Center for Innovative GYN Care are a few of the noteworthy initiatives.
In order to spread awareness about fibroids, The White Dress Project organization educates women about the essentials while also raising money for research. Women are encouraged to join and participate in this project and to share their stories. The Fibroids Project is a website and community dedicated to assisting women in eradicating their fibroids. Their goal is to arm medical professionals and women with complete knowledge about recent research, initiatives, and practices. The market growth is projected to be boosted by women's rising knowledge of uterine fibroids, their treatment, and activities.
The Uterine Fibroid Treatment Device Market segmentation, based on Technology includes Surgical Techniques, Laparoscopic Techniques, Ablation Techniques, and Embolization Techniques. The surgical techniques segment dominated the overall market with a share of 33.9% in 2022. The most common surgical procedures for treating fibroids in women are hysterectomy and myomectomy, which account for the rise in their number. Additionally, this method is the most popular and effective long-term cure for uterine fibroids. Thus, a rise in associated surgeries is anticipated to support segment expansion.
The ablation methods market is anticipated to grow at the highest CAGR of 10.2%. The uterine endometrial lining is surgically removed using this least invasive method. This surgical procedure is frequently used to treat severe menstrual bleeding. Endometrial ablation does not require incisions and can be performed at the doctor's office without requiring general anesthesia. In addition, pregnancy is feasible following endometrial ablation. Benefits provided by ablation procedures are therefore anticipated to drive the segment's expansion.
The Uterine Fibroid Treatment Device Market segmentation, based on Mode of Treatment, includes Invasive Treatment, Minimally Invasive Treatment, and Non-invasive Treatment. This is explained by the rise in uterine fibroids incidences and symptoms in females all over the world. Due to their low cost and general acceptance, abdominal myomectomy and hysterectomy are the two most effective treatments for uterine fibroids. Therefore, it is projected that during the projection period, these factors would enhance demand for uterine fibroids treatment devices.
Figure 1: Uterine Fibroid Treatment Device Market, by Mode of Treatment, 2022 & 2032 (USD Billion)
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
By region, the study provides the market insights into North America, Europe, Asia-Pacific and Rest of the World. The North America Uterine Fibroid Treatment Device Market dominated this market in 2022 (45.80%). This is explained by the region's existence of reputable medical institutions, growing government initiatives, and an increase in hysterectomy-related surgeries and hospital admissions.
Additionally, the availability of cutting-edge goods and the presence of significant important players like Medtronic, Stryker, and CooperSurgical, Inc. are fostering market expansion in the area. Additionally, the availability of strong distribution channels and the ease of access to healthcare technology are encouraging the use of uterine fibroids treatment equipment in the area. Further, the U.S. Uterine Fibroid Treatment Device market held the largest market share, and the Canada Uterine Fibroid Treatment Device market was the fastest growing market in the North America region.
Further, the major countries studied in the market report are The U.S., Canada, German, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.
Figure 2: Uterine Fibroid Treatment Device Market SHARE BY REGION 2022 (USD Billion)
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
Europe Uterine Fibroid Treatment Device market accounts for the second-largest market share. Due to its sophisticated healthcare system and rising knowledge of minimally invasive treatment options, Europe is predicted to have a sizable market for uterine fibroid treatment devices. The United Kingdom, France, and Germany are projected to make significant contributions to the market's expansion. The market in this area is projected to expand due to the desire for non-surgical and minimally invasive treatment alternatives including MRI-guided focused ultrasound (MRgFUS) and uterine artery embolization. Further, the German Uterine Fibroid Treatment Device market held the largest market share, and the UK Uterine Fibroid Treatment Device market was the fastest growing market in the European region
The Asia-Pacific Uterine Fibroid Treatment Device Market is expected to grow at the fastest CAGR from 2023 to 2032. This is because there are many people and more people are conscious of their health needs, which creates a sizable market opportunity for uterine fibroid treatment devices. Because uterine fibroids are becoming more common and because healthcare costs are rising, nations like China, India, and Japan are anticipated to lead market expansion. However, considerations including regulatory difficulties and disparities in the region's nations' healthcare infrastructure could have an impact on market expansion. Moreover, China’s Uterine Fibroid Treatment Device market held the largest market share, and the Indian Uterine Fibroid Treatment Device market was the fastest growing market in the Asia-Pacific region.
Leading market players are investing heavily in research and development in order to expand their product lines, which will help the Uterine Fibroid Treatment Device market, grow even more. Market participants are also undertaking a variety of strategic activities to expand their global footprint, with important market developments including new product launches, contractual agreements, mergers and acquisitions, higher investments, and collaboration with other organizations. To expand and survive in a more competitive and rising market climate, Uterine Fibroid Treatment Device industry must offer cost-effective items.
Manufacturing locally to minimize operational costs is one of the key business tactics used by manufacturers in the global Uterine Fibroid Treatment Device industry to benefit clients and increase the market sector. In recent years, the Uterine Fibroid Treatment Device industry has offered some of the most significant advantages to medicine. Major players in the Uterine Fibroid Treatment Device market, including Medtronic; Stryker Corporation; CooperSurgical Inc.; Ethicon, Inc.; Hologic, Inc.; Minerva Surgical, Inc.; Lumenis; Boston scientific; INSIGHTEC; Karl Storz GmbH, and others, are attempting to increase market demand by investing in research and development operations.
A medical technology firm called Medtronic Plc (Medtronic), originally known as Medtronic Inc., creates, develops, produces, and sells medical products. It provides products for the treatment of conditions such heart valve issues, heart failure, aortic, peripheral vascular, venous renal, and neurological problems, as well as spine and musculoskeletal issues, ear, nose, and throat conditions. Additionally, it offers biologic solutions for the dental and orthopedic markets. In Asia Pacific, Europe, the Americas, the Middle East, and Africa, it provides its products to hospitals, third-party healthcare providers, clinics, institutions, including governmental healthcare programs, distributors, and group purchasing groups. The headquarters of Medtronic are in Dublin, Ireland.
Stryker Corp (Stryker), a pioneer in medical technology, is a manufacturer of a range of orthopedic, medical, surgical, neurotechnology, and spine apparatus as well as associated services. Orthopedic implants, surgical tools and navigation systems, patient handling equipment, disposable intensive care supplies, and endoscopic and communication systems are among the company's primary products. Additionally, it provides spinal devices, neurosurgical equipment, and medical equipment for use in a variety of illnesses. Stryker sells items to physicians, hospitals, and other medical facilities. The corporation distributes its goods through subsidiaries, branches, independent dealers, and distributors in the Americas, Europe, Asia-Pacific, the Middle East, and Africa. Stryker's corporate office is located in Kalamazoo, Michigan, a city in the US.
Key Companies in the Uterine Fibroid Treatment Device Market Include
Stryker Corporation
CooperSurgical Inc
Ethicon, Inc.
Minerva Surgical, Inc.
Lumenis
Boston scientific
INSIGHTEC
Karl Storz GmbH
Uterine Fibroid Treatment Device Industry Developments
In March 2020, Tele Pack+ is a portable endoscopic system that Karl Storz has introduced. It is a portable video system that combines all of the essential elements—such as the camera control unit, light source, and display—needed for data management, diagnosis, and therapy.
In 2021, The MyoSure® line of devices from Hologic, Inc. have been given the go-ahead by the American Food and Drug Administration (FDA) for the removal of intrauterine tissue, including uterine fibroids. The MyoSure product line consists of three different treatments for uterine fibroids: MyoSure REACH, MyoSure XL, and MyoSure LITE..
In 2021, The debut of the EmprintTM Ablation System with ThermosphereTM Technology was announced by Medtronic Plc. This technology is made to give doctors more control and accuracy when performing the treatment to remove uterine fibroids using radiofrequency energy.
In 2020, The THUNDERBEAT Front-actuated Grip (FLEX) Surgical Tissue Management System was introduced by Olympus Corporation. This technology is made to give surgeons more control and accuracy during uterine fibroids minimally invasive operations.
In 2020, Launch of the TRUCLEAR 5C Hysteroscope and Resectoscope System was announced by Smith & Nephew plc. During hysteroscopic operations for uterine fibroids, this technology is intended to give doctors more visibility and control.
Surgical Techniques
Laparoscopic Techniques
Ablation Techniques
Embolization Techniques
Invasive Treatment
Minimally Invasive Treatment
Non-invasive Treatment
North America
U.S.
Canada
Europe
Germany
France
UK
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Australia
Rest of Asia-Pacific
Rest of the World
Middle East
Africa
Latin America
| Report Attribute/Metric | Details |
| Market Size 2022 | USD 5.2 Billion |
| Market Size 2023 | USD 5.73 Billion |
| Market Size 2032 | USD 12.46 Billion |
| Compound Annual Growth Rate (CAGR) | 10.20% (2023-2032) |
| Base Year | 2022 |
| Market Forecast Period | 2023-2032 |
| Historical Data | 2018- 2022 |
| Market Forecast Units | Value (USD Billion) |
| Report Coverage | Revenue Forecast, Market Competitive Landscape, Growth Factors, and Trends |
| Segments Covered | Technology, Mode of Treatment, and Region |
| Geographies Covered | North America, Europe, Asia Pacific, and the Rest of the World |
| Countries Covered | The U.S., Canada, German, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil |
| Key Companies Profiled | Medtronic; Stryker Corporation; CooperSurgical Inc.; Ethicon, Inc.; Hologic, Inc.; Minerva Surgical, Inc.; Lumenis; Boston scientific; INSIGHTEC; Karl Storz GmbH |
| Key Market Opportunities | Rapid Technological Advancements |
| Key Market Dynamics | Stringent Regulatory Framework |
Uterine Fibroid Treatment Device Market Highlights:
Frequently Asked Questions (FAQ) :
The Uterine Fibroid Treatment Device Market size was valued at USD 5.2 Billion in 2022.
The global market is projected to grow at a CAGR of 10.20% during the forecast period, 2023-2032.
North America had the largest share in the global market
The key players in the market are Medtronic; Stryker Corporation; CooperSurgical Inc.; Ethicon, Inc.; Hologic, Inc.; Minerva Surgical, Inc.; Lumenis; Boston scientific; INSIGHTEC; Karl Storz GmbH
The Surgical Techniques category dominated the market in 2022.
The Invasive Treatment had the largest share in the global market.
Leading companies partner with us for data-driven Insights.
Kindly complete the form below to receive a free sample of this Report
Assistant Manager He holds an experience of about 7+ years in market research and business consulting, working under the spectrum of life sciences and healthcare domains. rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. his expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. in addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives
Get in Touch
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
